"Stanford Team Achieves Breakthrough in Breast Cancer Research"

Stanford researchers, led by Dr. Lingyin Li, have published a study revealing the role of the enzyme ENPP1 in breast cancer progression. ENPP1 breaks down cGAMP, a molecule vital for activating the STING pathway in the immune system, which fights cancer. High levels of ENPP1 in tumors correlate with poor prognosis, while lower levels are associated with better responses to immunotherapy. The study suggests that targeting ENPP1 could enhance immunotherapy effectiveness and that ENPP1 levels could serve as a biomarker for treatment response. This breakthrough has significant implications for the development of new cancer treatments and has sparked interest among pharmaceutical companies in finding ENPP1 inhibitors.